MDM2 and endometrioid stromal sarcoma: Due to the oncogenic effects of HG-ESS gene rearrangement on the cell-cycle checkpoints and the downstream activation of cyclin D1 [54,55] or MDM2 amplification [55], CDK4/6 inhibitors and MDM2 inhibitors are another potential therapeutic option for HG-ESS that are currently being investigated in preclinical [54] and clinical trials [36].